CFA
ZNTL icon

Carroll Financial Associates’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Carroll Financial Associates’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$0 Hold
10
– – ﹤0.01% 1986
2021
Q3 		$0 Hold
10
– – ﹤0.01% 1976
2021
Q2 		$0 Hold
10
– – ﹤0.01% 1874
2021
Q1 		$0 Hold
10
– – ﹤0.01% 1788
2020
Q4 		$0 Buy
+10
New +$451 ﹤0.01% 1698

Other funds holding ZNTL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Carroll Financial Associates's ZNTL Position: Q4 2021 in Review

Carroll Financial Associates held its Zentalis Pharmaceuticals (ZNTL) position steady in Q4 2021 at 10 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1986.

Carroll Financial Associates first reported a position in ZNTL in Q4 2020 and has held it in 5 quarters since. 139 funds tracked by Wall St. Rank hold ZNTL as of Q4 2021.

  • Carroll Financial Associates held 10 shares of Zentalis Pharmaceuticals worth $0 as of Q4 2021.
  • Carroll Financial Associates left its Zentalis Pharmaceuticals share count unchanged in Q4 2021.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Carroll Financial Associates's portfolio in Q4 2021, its #1986 holding.
  • Carroll Financial Associates first reported a position in Zentalis Pharmaceuticals in Q4 2020 and has held it in 5 quarters since.
  • 139 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2021.

Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.